1
|
Chang Y, Liang Y, Wu H, Li L, Yang B, Jiang L, Ren Q, Pei X. Adaptive assessment based on fractional CBCT images for cervical cancer. J Appl Clin Med Phys 2024:e14462. [PMID: 39072895 DOI: 10.1002/acm2.14462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 06/25/2024] [Accepted: 06/27/2024] [Indexed: 07/30/2024] Open
Abstract
PURPOSE Anatomical and other changes during radiotherapy will cause inaccuracy of dose distributions, therefore the expectation for online adaptive radiation therapy (ART) is high in effectively reducing uncertainties due to intra-variation. However, ART requires extensive time and effort. This study investigated an adaptive assessment workflow based on fractional cone-beam computed tomography (CBCT) images. METHODS Image registration, synthetic CT (sCT) generation, auto-segmentation, and dose calculation were implemented and integrated into ArcherQA Adaptive Check. The rigid registration was based on ITK open source. The deformable image registration (DIR) method was based on a 3D multistage registration network, and the sCT generation method was performed based on a 2D cycle-consistent adversarial network (CycleGAN). The auto-segmentation of organs at risk (OARs) on sCT images was finished by a deep learning-based auto-segmentation software, DeepViewer. The contours of targets were obtained by the structure-guided registration. Finally, the dose calculation was based on a GPU-based Monte Carlo (MC) dose code, ArcherQA. RESULTS The dice similarity coefficient (DSCs) were over 0.86 for target volumes and over 0.79 for OARs. The gamma pass rate of ArcherQA versus Eclipse treatment planning system was more than 99% at the 2%/2 mm criterion with a low-dose threshold of 10%. The time for the whole process was less than 3 min. The dosimetric results of ArcherQA Adaptive Check were consistent with the Ethos scheduled plan, which can effectively identify the fractions that need the implementation of the Ethos adaptive plan. CONCLUSION This study integrated AI-based technologies and GPU-based MC technology to evaluate the dose distributions using fractional CBCT images, demonstrating remarkably high efficiency and precision to support future ART processes.
Collapse
Affiliation(s)
- Yankui Chang
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
| | - Yongguang Liang
- Department of Radiation Oncology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
| | - Haotian Wu
- Anhui Wisdom Technology Company Limited, Hefei, China
| | - Lingyan Li
- Anhui Wisdom Technology Company Limited, Hefei, China
| | - Bo Yang
- Department of Radiation Oncology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
| | - Lipeng Jiang
- Department of Radiation Oncology, First Affiliated Hospital of Jinzhou Medical University, Shenyang, China
| | - Qiang Ren
- Anhui Wisdom Technology Company Limited, Hefei, China
| | - Xi Pei
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
- Anhui Wisdom Technology Company Limited, Hefei, China
| |
Collapse
|
2
|
Adam DP, Grudzinski JJ, Marsh IR, Hill PM, Cho SY, Bradshaw TJ, Longcor J, Burr A, Bruce JY, Harari PM, Bednarz BP. Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2024; 119:1275-1284. [PMID: 38367914 DOI: 10.1016/j.ijrobp.2024.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 12/20/2023] [Accepted: 02/08/2024] [Indexed: 02/19/2024]
Abstract
PURPOSE Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment for patients with recurrent head and neck cancer. This work establishes a patient-specific dosimetry framework that combines Monte Carlo-based dosimetry from the 2 radiation modalities at the voxel level using deformable image registration (DIR) and radiobiological constructs for patients enrolled in a phase 1 clinical trial combining EBRT and RPT. METHODS AND MATERIALS Serial single-photon emission computed tomography (SPECT)/computed tomography (CT) patient scans were performed at approximately 24, 48, 72, and 168 hours postinjection of 577.2 MBq/m2 (15.6 mCi/m2) CLR 131, an iodine 131-containing RPT agent. Using RayStation, clinical EBRT treatment plans were created with a treatment planning CT (TPCT). SPECT/CT images were deformably registered to the TPCT using the Elastix DIR module in 3D Slicer software and assessed by measuring mean activity concentrations and absorbed doses. Monte Carlo EBRT dosimetry was computed using EGSnrc. RPT dosimetry was conducted using RAPID, a GEANT4-based RPT dosimetry platform. Radiobiological metrics (biologically effective dose and equivalent dose in 2-Gy fractions) were used to combine the 2 radiation modalities. RESULTS The DIR method provided good agreement for the activity concentrations and calculated absorbed dose in the tumor volumes for the SPECT/CT and TPCT images, with a maximum mean absorbed dose difference of -11.2%. Based on the RPT absorbed dose calculations, 2 to 4 EBRT fractions were removed from patient EBRT treatments. For the combined treatment, the absorbed dose to target volumes ranged from 57.14 to 75.02 Gy. When partial volume corrections were included, the mean equivalent dose in 2-Gy fractions to the planning target volume from EBRT + RPT differed -3.11% to 1.40% compared with EBRT alone. CONCLUSIONS This work demonstrates the clinical feasibility of performing combined EBRT + RPT dosimetry on TPCT scans. Dosimetry guides treatment decisions for EBRT, and this work provides a bridge for the same paradigm to be implemented within the rapidly emerging clinical RPT space.
Collapse
Affiliation(s)
- David P Adam
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Joseph J Grudzinski
- Department of Radiology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| | - Ian R Marsh
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Patrick M Hill
- Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| | - Steve Y Cho
- Department of Radiology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
| | - Tyler J Bradshaw
- Department of Radiology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| | | | - Adam Burr
- Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
| | - Justine Y Bruce
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| | - Paul M Harari
- Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
| | - Bryan P Bednarz
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.
| |
Collapse
|
3
|
Zhou P, Chang Y, Li S, Luo J, Lei L, Shang Y, Pei X, Ren Q, Chen C. Clinical application of a GPU-accelerated monte carlo dose verification for cyberknife M6 with Iris collimator. Radiat Oncol 2024; 19:86. [PMID: 38956685 PMCID: PMC11221037 DOI: 10.1186/s13014-024-02446-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Accepted: 04/29/2024] [Indexed: 07/04/2024] Open
Abstract
PURPOSE To apply an independent GPU-accelerated Monte Carlo (MC) dose verification for CyberKnife M6 with Iris collimator and evaluate the dose calculation accuracy of RayTracing (TPS-RT) algorithm and Monte Carlo (TPS-MC) algorithm in the Precision treatment planning system (TPS). METHODS GPU-accelerated MC algorithm (ArcherQA-CK) was integrated into a commercial dose verification system, ArcherQA, to implement the patient-specific quality assurance in the CyberKnife M6 system. 30 clinical cases (10 cases in head, and 10 cases in chest, and 10 cases in abdomen) were collected in this study. For each case, three different dose calculation methods (TPS-MC, TPS-RT and ArcherQA-CK) were implemented based on the same treatment plan and compared with each other. For evaluation, the 3D global gamma analysis and dose parameters of the target volume and organs at risk (OARs) were analyzed comparatively. RESULTS For gamma pass rates at the criterion of 2%/2 mm, the results were over 98.0% for TPS-MC vs.TPS-RT, TPS-MC vs. ArcherQA-CK and TPS-RT vs. ArcherQA-CK in head cases, 84.9% for TPS-MC vs.TPS-RT, 98.0% for TPS-MC vs. ArcherQA-CK and 83.3% for TPS-RT vs. ArcherQA-CK in chest cases, 98.2% for TPS-MC vs.TPS-RT, 99.4% for TPS-MC vs. ArcherQA-CK and 94.5% for TPS-RT vs. ArcherQA-CK in abdomen cases. For dose parameters of planning target volume (PTV) in chest cases, the deviations of TPS-RT vs. TPS-MC and ArcherQA-CK vs. TPS-MC had significant difference (P < 0.01), and the deviations of TPS-RT vs. TPS-MC and TPS-RT vs. ArcherQA-CK were similar (P > 0.05). ArcherQA-CK had less calculation time compared with TPS-MC (1.66 min vs. 65.11 min). CONCLUSIONS Our proposed MC dose engine (ArcherQA-CK) has a high degree of consistency with the Precision TPS-MC algorithm, which can quickly identify the calculation errors of TPS-RT algorithm for some chest cases. ArcherQA-CK can provide accurate patient-specific quality assurance in clinical practice.
Collapse
Affiliation(s)
- Peng Zhou
- Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China
| | - Yankui Chang
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
| | - Shijun Li
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
| | - Jia Luo
- Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China
| | - Lin Lei
- Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China
| | - Yufen Shang
- Department of Radiation Oncology, Dezhou Second People's Hospital, Dezhou, China
| | - Xi Pei
- Anhui Wisdom Technology Company Limited, Hefei, China
| | - Qiang Ren
- Anhui Wisdom Technology Company Limited, Hefei, China.
| | - Chuan Chen
- Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
| |
Collapse
|
4
|
Rehani MM, Xu XG. Dose, dose, dose, but where is the patient dose? RADIATION PROTECTION DOSIMETRY 2024; 200:945-955. [PMID: 38847407 DOI: 10.1093/rpd/ncae137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/14/2024] [Accepted: 05/17/2024] [Indexed: 06/25/2024]
Abstract
The article reviews the historical developments in radiation dose metrices in medical imaging. It identifies the good, the bad, and the ugly aspects of current-day metrices. The actions on shifting focus from International Commission on Radiological Protection (ICRP) Reference-Man-based population-average phantoms to patient-specific computational phantoms have been proposed and discussed. Technological developments in recent years involving AI-based automatic organ segmentation and 'near real-time' Monte Carlo dose calculations suggest the feasibility and advantage of obtaining patient-specific organ doses. It appears that the time for ICRP and other international organizations to embrace 'patient-specific' dose quantity representing risk may have finally come. While the existing dose metrices meet specific demands, emphasis needs to be also placed on making radiation units understandable to the medical community.
Collapse
Affiliation(s)
- Madan M Rehani
- Massachusetts General Hospital, Radiology Department, Boston, MA, 02114, United States
| | - Xie George Xu
- University of Science and Technology of China (USTC), College of Nuclear Science & Technology, Hefei, Anhui Province, 230026, China
| |
Collapse
|
5
|
Li S, Cheng B, Wang Y, Pei X, Xu XG. A GPU-based fast Monte Carlo code that supports proton transport in magnetic field for radiation therapy. J Appl Clin Med Phys 2024; 25:e14208. [PMID: 37987549 PMCID: PMC10795429 DOI: 10.1002/acm2.14208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 09/11/2023] [Accepted: 10/28/2023] [Indexed: 11/22/2023] Open
Abstract
This paper presents the effort to extend a previously reported code ARCHER, a GPU-based Monte Carlo (MC) code for coupled photon and electron transport, into protons including the consideration of magnetic fields. The proton transport is modeled using a Class-II condensed-history algorithm with continuous slowing-down approximation. The model includes ionization, multiple scattering, energy straggling, elastic and inelastic nuclear interactions, as well as deflection due to the Lorentz force in magnetic fields. An additional direction change is added for protons at the end of each step in the presence of the magnetic field. Secondary charge particles, except for protons, are terminated depositing kinetic energies locally, whereas secondary neutral particles are ignored. Each proton is transported step by step until its energy drops to below 0.5 MeV or when the proton leaves the phantom. The code is implemented using the compute unified device architecture (CUDA) platform for optimized GPU thread-level parallelism and efficiency. The code is validated by comparing it against TOPAS. Comparisons of dose distributions between our code and TOPAS for several exposure scenarios, ranging from single square beams in water to patient plan with magnetic fields, show good agreement. The 3D-gamma pass rate with a 2 mm/2% criterion in the region with dose greater than 10% of the maximum dose is computed to be over 99% for all tested cases. Using a single NVIDIA TITAN V GPU card, the computational time of ARCHER is found to range from 0.82 to 4.54 seconds for 1 × 107 proton histories. Compared to a few hours running on TOPAS, this speed improvement is significant. This work presents, for the first time, the performance of a GPU-based MC code to simulate proton transportation magnetic fields, demonstrating the feasibility of accurate and efficient dose calculations in potential magnetic resonance imaging (MRI)-guided proton therapy.
Collapse
Affiliation(s)
- Shijun Li
- School of Nuclear Science and TechnologyUniversity of Science and Technology of ChinaHefeiChina
| | - Bo Cheng
- School of Nuclear Science and TechnologyUniversity of Science and Technology of ChinaHefeiChina
| | - Yuxin Wang
- School of Nuclear Science and TechnologyUniversity of Science and Technology of ChinaHefeiChina
| | - Xi Pei
- Anhui Wisdom Technology Company LimitedHefeiAnhuiChina
| | - Xie George Xu
- School of Nuclear Science and TechnologyUniversity of Science and Technology of ChinaHefeiChina
- Department of Radiation OncologyThe First Affiliated Hospital of USTCUniversity of Science and Technology of ChinaHefeiChina
| |
Collapse
|
6
|
Cheng B, Xu Y, Li S, Ren Q, Pei X, Men K, Dai J, Xu XG. Development and clinical application of a GPU-based Monte Carlo dose verification module and software for 1.5 T MR-LINAC. Med Phys 2023; 50:3172-3183. [PMID: 36862110 DOI: 10.1002/mp.16337] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 02/14/2023] [Accepted: 02/20/2023] [Indexed: 03/03/2023] Open
Abstract
BACKGROUND Adaptive radiotherapy (ART) has made significant advances owing to magnetic resonance linear accelerator (MR-LINAC), which provides superior soft-tissue contrast, fast speed and rich functional magnetic resonance imaging (MRI) to guide radiotherapy. Independent dose verification plays a critical role in discovering errors, while several challenges remain in MR-LINAC. PURPOSE A Monte Carlo-based GPU-accelerated dose verification module for Unity is proposed and integrated into the commercial software ArcherQA to achieve fast and accurate quality assurance (QA) for online ART. METHODS Electron or positron motion in a magnetic field was implemented, and a material-dependent step-length limit method was used to trade off speed and accuracy. Transport was verified by dose comparison with EGSnrc in three A-B-A phantoms. Then, an accurate Monte Carlo-based Unity machine model was built in ArcherQA, including an MR-LINAC head, cryostat, coils, and treatment couch. In particular, a mixed model combining measured attenuation and homogeneous geometry was adopted for the cryostat. Several parameters in the LINAC model were tuned to commission it in the water tank. An alternating open-closed MLC plan on solid water measured with EBT-XD film was used to verify the LINAC model. Finally, the ArcherQA dose was compared with ArcCHECK measurements and GPUMCD in 30 clinical cases through the gamma test. RESULTS ArcherQA and EGSnrc were well matched in three A-B-A phantom tests, and the relative dose difference (RDD) was less than 1.6% in the homogenous region. A Unity model was commissioned in the water tank, and the RDD in the homogenous region was less than 2%. In the alternating open-closed MLC plan, the gamma result (3%/3 mm) between ArcherQA and Film was 96.55%, better than the gamma result between GPUMCD and Film (92.13%). In 30 clinical cases, the mean three-dimensional (3D) gamma result (3%/2 mm) was 99.36% ± 1.28% between ArcherQA and ArcCHECK for the QA plans and 99.27% ± 1.04% between ArcherQA and GPUMCD for the clinical patient plans. The average dose calculation time was 106 s in all clinical patient plans. CONCLUSIONS A GPU-accelerated Monte Carlo-based dose verification module was developed and built for the Unity MR-LINAC. The fast speed and high accuracy were proven by comparison with EGSnrc, commission data, the ArcCHECK measurement dose, and the GPUMCD dose. This module can achieve fast and accurate independent dose verification for Unity.
Collapse
Affiliation(s)
- Bo Cheng
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
| | - Yuan Xu
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shijun Li
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China
| | - Qiang Ren
- Technology Development Department, Anhui Wisdom Technology Company Limited, Hefei, China
| | - Xi Pei
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China.,Technology Development Department, Anhui Wisdom Technology Company Limited, Hefei, China
| | - Kuo Men
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jianrong Dai
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xie George Xu
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China.,Department of Radiation Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China
| |
Collapse
|
7
|
The Software with a Graphical User Interface for GAMOS: Basic Training and an Educational Tool for Medical Physicists. POLISH JOURNAL OF MEDICAL PHYSICS AND ENGINEERING 2023. [DOI: 10.2478/pjmpe-2023-0005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
Abstract
Abstract
Introduction: It is necessary to have special experience to perform the Monte Carlo calculation, commonly used in medical physics and accepted as the gold standard. In this study, we developed software to teach basic steps to medical physicists who were inexperienced in the medical linear accelerator Monte Carlo simulation.
Material and methods: For the design interface, a software called GamosLinacGUI was developed using Gnome Builder, Python, and GTK. The user, who wants to learn the basics of GAMOS and simulate a linear accelerator, can enter the values in the software, select some options and quickly create geometry and physics files.
Results: For proof that the software generates the correct inputs for GAMOS simulation in the same conditions for the measurements and calculations. Required files for GAMOS have been created and tested and run the simulation accordingly. This software was tested with Centos Linux.
Conclusions: GamosLinacGUI has been successfully developed, which creates the geometry and physics files required for the simulation with GAMOS as a training and learning tool.
Collapse
|
8
|
Xu Y, Zhang K, Liu Z, Liang B, Ma X, Ren W, Men K, Dai J. Treatment plan prescreening for patient-specific quality assurance measurements using independent Monte Carlo dose calculations. Front Oncol 2022; 12:1051110. [PMID: 36419878 PMCID: PMC9676489 DOI: 10.3389/fonc.2022.1051110] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 10/19/2022] [Indexed: 11/22/2023] Open
Abstract
PURPOSE This study proposes a method to identify plans that failed patient-specific quality assurance (QA) and attempts to establish a criterion to prescreen treatment plans for patient-specific QA measurements with independent Monte Carlo dose calculations. MATERIALS AND METHODS Patient-specific QA results measured with an ArcCHECK diode array of 207 patients (head and neck: 25; thorax: 61; abdomen: 121) were retrospectively analyzed. All patients were treated with the volumetric modulated arc therapy (VMAT) technique and plans were optimized with a Pinnacle v16.2 treatment planning system using an analytical algorithm-based dose engine. Afterwards, phantom verification plans were designed and recalculated by an independent GPU-accelerated Monte Carlo (MC) dose engine, ArcherQA. Moreover, sensitivity and specificity analyzes of gamma passing rates between measurements and MC calculations were carried out to show the ability of MC to monitor failing plans (ArcCHECK 3%/3 mm,<90%), and attempt to determine the appropriate threshold and gamma passing rate criterion utilized by ArcherQA to prescreen treatment plans for ArcCHECK measurements. The receiver operator characteristic (ROC) curve was also utilized to characterize the performance of different gamma passing rate criterion used by ArcherQA. RESULTS The thresholds for 100% sensitivity to detect plans that failed patient-specific QA by independent calculation were 97.0%, 95.4%, and 91.0% for criterion 3%/3 mm, 3%/2 mm, and 2%/2 mm, respectively, which corresponded to specificities of 0.720, 0.528, and 0.585, respectively. It was shown that the 3%/3 mm criterion with 97% threshold for ArcherQA demonstrated perfect sensitivity and the highest specificity compared with other criteria, which may be suitable for prescreening treatment plans treated with the investigated machine to implement measurement-based patient-specific QA of patient plans. In addition, the area under the curve (AUC) calculated from ROC analysis for criterion 3%/3 mm, 3%/2 mm, and 2%/2 mm used by ArcherQA were 0.948, 0.924, and 0.929, respectively. CONCLUSIONS Independent dose calculation with the MC-based program ArcherQA has potential as a prescreen treatment for measurement-based patient-specific QA. AUC values (>0.9) showed excellent classification accuracy for monitoring failing plans with independent MC calculations.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Kuo Men
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jianrong Dai
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
9
|
Kollitz E, Roew M, Han H, Pinto M, Kamp F, Kim CH, Schwarz M, Belka C, Newhauser W, Parodi K, Dedes G. Applications of a patient-specific whole-body CT-mesh hybrid computational phantom in second cancer risk prediction. Phys Med Biol 2022; 67. [DOI: 10.1088/1361-6560/ac8851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 08/09/2022] [Indexed: 11/11/2022]
Abstract
Abstract
Objective. CT-mesh hybrid phantoms (or ‘hybrid(s)’) made from integrated patient CT data and mesh-type reference computational phantoms (MRCPs) can be beneficial for patient-specific whole-body dose evaluation, but this benefit has yet to be evaluated for second cancer risk prediction. The purpose of this study is to compare the hybrid’s ability to predict risk throughout the body with a patient-scaled MRCP against ground truth whole-body CTs (WBCTs). Approach. Head and neck active scanning proton treatment plans were created for and simulated on seven hybrids and the corresponding scaled MRCPs and WBCTs. Equivalent dose throughout the body was calculated and input into five second cancer risk models for both excess absolute and excess relative risk (EAR and ERR). The hybrid phantom was evaluated by comparing equivalent dose and risk predictions against the WBCT. Main results. The hybrid most frequently provides whole-body second cancer risk predictions which are closer to the ground truth when compared to a scaled MRCP alone. The performance of the hybrid relative to the scaled MRCP was consistent across ERR, EAR, and all risk models. For all in-field organs, where the hybrid shares the WBCT anatomy, the hybrid was better than or equal to the scaled MRCP for both equivalent dose and risk prediction. For out-of-field organs across all patients, the hybrid’s equivalent dose prediction was superior than the scaled MRCP in 48% of all comparisons, equivalent for 34%, and inferior for 18%. For risk assessment in the same organs, the hybrid’s prediction was superior than the scaled MRCP in 51.8% of all comparisons, equivalent in 28.6%, and inferior in 19.6%. Significance. Whole-body risk predictions from the CT-mesh hybrid have shown to be more accurate than those from a reference phantom alone. These hybrids could aid in risk-optimized treatment planning and individual risk assessment to minimize second cancer incidence.
Collapse
|
10
|
Peng Z, Lu Y, Xu Y, Li Y, Cheng B, Ni M, Chen Z, Pei X, Xie Q, Wang S, Xu XG. Development of a GPU-accelerated Monte Carlo dose calculation module for nuclear medicine, ARCHER-NM: demonstration for a PET/CT imaging procedure. Phys Med Biol 2022; 67. [DOI: 10.1088/1361-6560/ac58dd] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Accepted: 02/25/2022] [Indexed: 11/11/2022]
Abstract
Abstract
Objective. This paper describes the development and validation of a GPU-accelerated Monte Carlo (MC) dose computing module dedicated to organ dose calculations of individual patients undergoing nuclear medicine (NM) internal radiation exposures involving PET/CT examination. Approach. This new module extends the more-than-10-years-long ARCHER project that developed a GPU-accelerated MC dose engine by adding dedicated NM source-definition features. To validate the code, we compared dose distributions from the point ion source, including 18F, 11C, 15O, and 68Ga, calculated for a water phantom against a well-tested MC code, GATE. To demonstrate the clinical utility and advantage of ARCHER-NM, one set of 18F-FDG PET/CT data for an adult male NM patient is calculated using the new code. Radiosensitive organs in the CT dataset are segmented using a CNN-based tool called DeepViewer. The PET image intensity maps are converted to radioactivity distributions to allow for MC radiation transport dose calculations at the voxel level. The dose rate maps and corresponding statistical uncertainties were calculated at the acquisition time of PET image. Main results. The water-phantom results show excellent agreement, suggesting that the radiation physics module in the new NM code is adequate. The dose rate results of the 18F-FDG PET imaging patient show that ARCHER-NM’s results agree very well with those of the GATE within −2.45% to 2.58% (for a total of 28 organs considered in this study). Most impressively, ARCHER-NM obtains such results in 22 s while it takes GATE about 180 min for the same number of 5 × 108 simulated decay events. Significance. This is the first study presenting GPU-accelerated patient-specific MC internal radiation dose rate calculations for clinically realistic 18F-FDG PET/CT imaging case involving autosegmentation of whole-body PET/CT images. This study suggests that the proposed computing tools—ARCHER-NM— are accurate and fast enough for routine internal dosimetry in NM clinics.
Collapse
|